PHVS
Pharvaris N.V.$33.41-0.12 (-0.36%)Prev Close$33.53·MCap$2.34B·P/E—·Vol169.4K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
43
$32.50M
◆
Net Activity
Net Seller
$32.50M
●
Active Insiders
11
last 12 mo
Over the past 12 months, insider activity at Pharvaris N.V. (PHVS) has been exclusively selling, with 0 insider purchases totaling $0.00 and 43 insider sales totaling $32.50M. The most recent insider transaction was by Monges Viviane (director), who sold $395.5K worth of shares on Sep 25, 2026. Pharvaris N.V. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $2.34B.
PHVS Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 25, 2026 | Monges Viviane | director | Sell | 11,969 | $33.05 | $395.5K | 5,500-69% |
| Sep 24, 2026 | Schikan Johannes Gerardus Christiaan Petrus | director | Sell | 800 | $36.19 | $29.0K | 115,167 |
| Sep 23, 2026 | Nassif David W. | officer: CFO / CLO | Sell | 6,000 | $36.47 | $218.8K | 114,300 |
| Sep 21, 2026 | Lu Peng | officer: President | Sell | 100,000 | $35.00 | $3.50M | 64,953-61% |
| Sep 21, 2026 | Glassman Robert | director | Sell | 14,493 | $38.56 | $558.8K | 10,500-58% |
| Sep 21, 2026 | Schikan Johannes Gerardus Christiaan Petrus | director | Sell | 200,000 | $35.00 | $7.00M | 115,167-63% |
| Sep 21, 2026 | Lesage Anne | officer: Chief Early Development | Sell | 20,000 | $38.27 | $765.5K | 73,969 |
| Sep 21, 2026 | Bjork Elisabeth | director | Sell | 52,500 | $37.89 | $1.99M | 15,167-78% |
| Sep 17, 2026 | Abele Stefan Andreas | officer: Chief Technical Ops Officer | Sell | 46,400 | $38.17 | $1.77M | 40,468-53% |
| Sep 17, 2026 | Glassman Robert | director | Sell | 8,667 | $38.27 | $331.7K | 10,500-45% |
| Sep 16, 2026 | Souverijns Wim | officer: Chief Commercial Officer | Sell | 26,090 | $39.23 | $1.02M | 45,111-37% |
| Sep 15, 2026 | Lu Peng | officer: President | Sell | 15,000 | $40.13 | $601.9K | 65,179 |
| Sep 15, 2026 | Modig Berndt | director, officer: Chief Executive Officer | Sell | 2,291 | $39.40 | $90.3K | 128,334 |
| Sep 14, 2026 | Lesage Anne | officer: Chief Early Development | Sell | 30,000 | $38.30 | $1.15M | 56,450-35% |
| Sep 11, 2026 | Glassman Robert | director | Sell | 8,000 | $37.55 | $300.4K | 10,500-43% |
| Sep 9, 2026 | Lu Peng | officer: President | Sell | 15,000 | $40.68 | $610.1K | 65,179 |
| Aug 18, 2026 | Modig Berndt | director, officer: Chief Executive Officer | Sell | 2,292 | $34.77 | $79.7K | 130,625 |
| Jul 15, 2026 | Modig Berndt | director, officer: Chief Executive Officer | Sell | 2,292 | $34.97 | $80.2K | 132,917 |
| Jul 1, 2026 | Lesage Anne | officer: Chief Early Development | Sell | 76,172 | $35.39 | $2.70M | 124,672-38% |
| Jul 1, 2026 | Schikan Johannes Gerardus Christiaan Petrus | director | Sell | 37,600 | $35.41 | $1.33M | 345,879 |
| Jun 29, 2026 | Lu Peng | officer: Chief Medical Officer | Sell | 29,700 | $34.30 | $1.02M | 69,031-30% |
| Jun 29, 2026 | Schikan Johannes Gerardus Christiaan Petrus | director | Sell | 2,400 | $35.10 | $84.2K | 352,767 |
| Jun 29, 2026 | Lesage Anne | officer: Chief Early Development | Sell | 2,300 | $35.12 | $80.8K | 131,669 |
| Jun 23, 2026 | Lu Peng | officer: Chief Medical Officer | Sell | 300 | $34.00 | $10.2K | 65,631 |
| Jun 17, 2026 | Modig Berndt | director, officer: Chief Executive Officer | Sell | 2,291 | $31.07 | $71.2K | 135,309 |
| Jun 8, 2026 | Nijdam Anna | officer: Principal Accounting Officer | Sell | 2,670 | $30.87 | $82.4K | 46,275 |
| May 26, 2026 | Monges Viviane | director | Sell | 9,667 | $30.29 | $292.9K | 5,500-64% |
| May 26, 2026 | Nassif David W. | officer: CFO / CLO | Sell | 10,000 | $30.31 | $303.1K | 120,300 |
| May 26, 2026 | Nijdam Anna | officer: Principal Accounting Officer | Sell | 7,330 | $30.70 | $225.1K | 48,945 |
| May 22, 2026 | Bjork Elisabeth | director | Sell | 10,000 | $29.32 | $293.2K | 15,167-40% |
| May 20, 2026 | Modig Berndt | director, officer: Chief Executive Officer | Sell | 2,292 | $29.22 | $67.0K | 137,500 |
| May 19, 2026 | Souverijns Wim | officer: Chief Commercial Officer | Sell | 10,000 | $29.92 | $299.2K | 45,111 |
| May 19, 2026 | Glassman Robert | director | Sell | 10,000 | $29.82 | $298.2K | 15,167-40% |
| May 19, 2026 | Abele Stefan Andreas | officer: Chief Technical Ops Officer | Sell | 8,748 | $29.82 | $260.9K | 35,194 |
| May 5, 2026 | Lu Peng | officer: Chief Medical Officer | Sell | 14,166 | $30.17 | $427.4K | 66,226 |
| May 1, 2026 | Lu Peng | officer: Chief Medical Officer | Sell | 18,733 | $30.21 | $565.9K | 66,083 |
| May 1, 2026 | Lesage Anne | officer: Chief Early Development | Sell | 40,900 | $30.24 | $1.24M | 153,169 |
| May 1, 2026 | Schikan Johannes Gerardus Christiaan Petrus | director | Sell | 32,900 | $30.29 | $996.5K | 384,237 |
| Apr 24, 2026 | Lesage Anne | officer: Chief Early Development | Sell | 7,600 | $30.05 | $228.4K | 156,969 |
| Apr 24, 2026 | Lu Peng | officer: Chief Medical Officer | Sell | 7,101 | $30.05 | $213.4K | 66,083 |
| Apr 24, 2026 | Schikan Johannes Gerardus Christiaan Petrus | director | Sell | 7,100 | $30.05 | $213.4K | 388,167 |
| Apr 20, 2026 | Modig Berndt | director, officer: Chief Executive Officer | Sell | 2,292 | $28.60 | $65.6K | 139,792 |
| Apr 10, 2026 | Modig Berndt | director, officer: Chief Executive Officer | Sell | 23,333 | $27.74 | $647.3K | 142,284 |
PHVS Insider Buying Activity
The following table shows recent insider purchases of Pharvaris N.V. (PHVS) stock reported via SEC Form 4 filings.
No insider buying activity found for PHVS in the last 12 months.
PHVS Insider Selling Activity
The following table shows recent insider sales of Pharvaris N.V. (PHVS) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 25, 2026 | Monges Viviane | director | Sell | 11,969 | $33.05 | $395.5K | 5,500-69% |
| Sep 24, 2026 | Schikan Johannes Gerardus Christiaan Petrus | director | Sell | 800 | $36.19 | $29.0K | 115,167 |
| Sep 23, 2026 | Nassif David W. | officer: CFO / CLO | Sell | 6,000 | $36.47 | $218.8K | 114,300 |
| Sep 21, 2026 | Lu Peng | officer: President | Sell | 100,000 | $35.00 | $3.50M | 64,953-61% |
| Sep 21, 2026 | Glassman Robert | director | Sell | 14,493 | $38.56 | $558.8K | 10,500-58% |
| Sep 21, 2026 | Schikan Johannes Gerardus Christiaan Petrus | director | Sell | 200,000 | $35.00 | $7.00M | 115,167-63% |
| Sep 21, 2026 | Lesage Anne | officer: Chief Early Development | Sell | 20,000 | $38.27 | $765.5K | 73,969 |
| Sep 21, 2026 | Bjork Elisabeth | director | Sell | 52,500 | $37.89 | $1.99M | 15,167-78% |
| Sep 17, 2026 | Abele Stefan Andreas | officer: Chief Technical Ops Officer | Sell | 46,400 | $38.17 | $1.77M | 40,468-53% |
| Sep 17, 2026 | Glassman Robert | director | Sell | 8,667 | $38.27 | $331.7K | 10,500-45% |
| Sep 16, 2026 | Souverijns Wim | officer: Chief Commercial Officer | Sell | 26,090 | $39.23 | $1.02M | 45,111-37% |
| Sep 15, 2026 | Lu Peng | officer: President | Sell | 15,000 | $40.13 | $601.9K | 65,179 |
| Sep 15, 2026 | Modig Berndt | director, officer: Chief Executive Officer | Sell | 2,291 | $39.40 | $90.3K | 128,334 |
| Sep 14, 2026 | Lesage Anne | officer: Chief Early Development | Sell | 30,000 | $38.30 | $1.15M | 56,450-35% |
| Sep 11, 2026 | Glassman Robert | director | Sell | 8,000 | $37.55 | $300.4K | 10,500-43% |
| Sep 9, 2026 | Lu Peng | officer: President | Sell | 15,000 | $40.68 | $610.1K | 65,179 |
| Aug 18, 2026 | Modig Berndt | director, officer: Chief Executive Officer | Sell | 2,292 | $34.77 | $79.7K | 130,625 |
| Jul 15, 2026 | Modig Berndt | director, officer: Chief Executive Officer | Sell | 2,292 | $34.97 | $80.2K | 132,917 |
| Jul 1, 2026 | Lesage Anne | officer: Chief Early Development | Sell | 76,172 | $35.39 | $2.70M | 124,672-38% |
| Jul 1, 2026 | Schikan Johannes Gerardus Christiaan Petrus | director | Sell | 37,600 | $35.41 | $1.33M | 345,879 |
| Jun 29, 2026 | Lu Peng | officer: Chief Medical Officer | Sell | 29,700 | $34.30 | $1.02M | 69,031-30% |
| Jun 29, 2026 | Schikan Johannes Gerardus Christiaan Petrus | director | Sell | 2,400 | $35.10 | $84.2K | 352,767 |
| Jun 29, 2026 | Lesage Anne | officer: Chief Early Development | Sell | 2,300 | $35.12 | $80.8K | 131,669 |
| Jun 23, 2026 | Lu Peng | officer: Chief Medical Officer | Sell | 300 | $34.00 | $10.2K | 65,631 |
| Jun 17, 2026 | Modig Berndt | director, officer: Chief Executive Officer | Sell | 2,291 | $31.07 | $71.2K | 135,309 |
| Jun 8, 2026 | Nijdam Anna | officer: Principal Accounting Officer | Sell | 2,670 | $30.87 | $82.4K | 46,275 |
| May 26, 2026 | Monges Viviane | director | Sell | 9,667 | $30.29 | $292.9K | 5,500-64% |
| May 26, 2026 | Nassif David W. | officer: CFO / CLO | Sell | 10,000 | $30.31 | $303.1K | 120,300 |
| May 26, 2026 | Nijdam Anna | officer: Principal Accounting Officer | Sell | 7,330 | $30.70 | $225.1K | 48,945 |
| May 22, 2026 | Bjork Elisabeth | director | Sell | 10,000 | $29.32 | $293.2K | 15,167-40% |
| May 20, 2026 | Modig Berndt | director, officer: Chief Executive Officer | Sell | 2,292 | $29.22 | $67.0K | 137,500 |
| May 19, 2026 | Souverijns Wim | officer: Chief Commercial Officer | Sell | 10,000 | $29.92 | $299.2K | 45,111 |
| May 19, 2026 | Glassman Robert | director | Sell | 10,000 | $29.82 | $298.2K | 15,167-40% |
| May 19, 2026 | Abele Stefan Andreas | officer: Chief Technical Ops Officer | Sell | 8,748 | $29.82 | $260.9K | 35,194 |
| May 5, 2026 | Lu Peng | officer: Chief Medical Officer | Sell | 14,166 | $30.17 | $427.4K | 66,226 |
| May 1, 2026 | Lu Peng | officer: Chief Medical Officer | Sell | 18,733 | $30.21 | $565.9K | 66,083 |
| May 1, 2026 | Lesage Anne | officer: Chief Early Development | Sell | 40,900 | $30.24 | $1.24M | 153,169 |
| May 1, 2026 | Schikan Johannes Gerardus Christiaan Petrus | director | Sell | 32,900 | $30.29 | $996.5K | 384,237 |
| Apr 24, 2026 | Lesage Anne | officer: Chief Early Development | Sell | 7,600 | $30.05 | $228.4K | 156,969 |
| Apr 24, 2026 | Lu Peng | officer: Chief Medical Officer | Sell | 7,101 | $30.05 | $213.4K | 66,083 |
| Apr 24, 2026 | Schikan Johannes Gerardus Christiaan Petrus | director | Sell | 7,100 | $30.05 | $213.4K | 388,167 |
| Apr 20, 2026 | Modig Berndt | director, officer: Chief Executive Officer | Sell | 2,292 | $28.60 | $65.6K | 139,792 |
| Apr 10, 2026 | Modig Berndt | director, officer: Chief Executive Officer | Sell | 23,333 | $27.74 | $647.3K | 142,284 |
PHVS Insiders
Similar Stocks to PHVS
MRNA
Moderna, Inc.
$225.82+1.80%
$85.50B
REGN
Regeneron Pharmaceuticals, Inc.
$969.36+4.43%
$83.15B
RVMD
Revolution Medicines, Inc.
$190.88-0.20%
$39.42B
ALNY
Alnylam Pharmaceuticals, Inc.
$161.00-2.49%
$30.46B
UTHR
United Therapeutics Corporation
$595.67-0.51%
$25.15B
INCY
Incyte Corporation
$119.31-1.01%
$23.69B
INSM
Insmed Incorporated
$111.22-1.20%
$21.18B
EXEL
Exelixis, Inc.
$71.60+3.14%
$16.64B